SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake
Cancer
Roche, AbbVie’s Venclexta Stumbles Again, This Time in Myelodysplastic Syndromes
Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic syndromes.
June 17, 2025
 · 
1 min read
 · 
Tristan Manalac
National Institutes of Health (NIH) building
Government
Court Orders Restoration of Canceled NIH Grants, Calls Cuts ‘Appalling’
District Judge William Young, a nominee of Republican President Ronald Reagan, blasted the Trump administration’s NIH cuts as discriminatory and “bearing down on people of color because of their color.”
June 17, 2025
 · 
2 min read
 · 
Tristan Manalac
iStock, Yutthana Gaetgeaw
CDC
CDC Scientist Resigns in Protest as Kennedy Reshapes Vaccine Regulation
HHS Secretary Robert F. Kennedy Jr.’s actions in recent months have raised concerns that he is taking a heavy-handed and unilateral approach to vaccine policy in the U.S.
June 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Composite photo collage of hands hold money income chip casino jackpot exchange poker game profit usd isolated on painted background.
Mergers & acquisitions
A String of Biopharma Deals Has Piqued Analyst Interest in an M&A Return
Big Pharma executives have not been shy about their desire for deals, but companies have been battling macro headwinds alongside Trump’s policies on drug pricing and tariff threats.
June 17, 2025
 · 
3 min read
 · 
Annalee Armstrong
Business concept illustration of a businessman digging and mining to find treasure
Antibody-drug conjugate (ADC)
NextCure Joins China-ADC Gold Rush with $745M Simcere Deal
The deal gets NextCure the rights to Simcere’s novel ADC for solid tumors outside of China.
June 16, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
From left to right: Jeff Quillen, Foley Hoag; Jim Cirenza, DNB Bank; Andrew Meadow, Health Innovation Capital; Greg Benning, Back Bay Life Science Advisors; Jonathan Gertler, Back Bay Life Science Advisors
Collaboration
Partner-Seeking Biotechs Find Plenty of Hands To Shake as BIO2025 Kicks Off
At a satellite kickoff event to the annual BIO meeting, investment bankers and VCs gave reasons for optimism amid a ‘volatile’ period for the industry.
June 16, 2025
 · 
2 min read
 · 
Jef Akst
Climb up, hand help businessman build ladder
Weight loss
Lilly Notches ‘Top-Tier’ Weight Loss Results for Phase I Amylin/Tirzepatide Combo
At 12 weeks, weight loss ranged from 2.6% to 11.3%, compared to a gain of 0.2% in the placebo group. Guggenheim analysts were also impressed by the tolerability profile.
June 16, 2025
 · 
2 min read
 · 
Annalee Armstrong
Working man icon pushing the load on the line. Hard work, labor, effort and determination concept.
Parkinson’s disease
Roche, Prothena Push Parkinson’s Drug to Phase III Despite Mid-Stage Fail
Analysts at Jefferies give Roche and Prothena’s Phase III study just a 25% to 40% probability of success.
June 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Digital collage modern art. Hands reaching together and shaking, with loading icon
Mergers & acquisitions
Regeneron Backs Off 23andMe, Losing Bid to Former CEO
Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” according to a spokesperson for the pharma.
June 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS